Kodiak Sciences reports Q1 net loss $0.94/sh; Zenkuda GLOW2 positive, BLA planned

Kodiak Sciences Inc.

2026-Q1 EPS reported -$0.94

Cash $169.5M as of March 31, 2026, expected to fund operations into 2027.
Net loss $58.2M ($0.94/sh) vs. $57.5M ($1.09/sh) in Q1 2025.
Zenkuda GLOW2: 62.5% ≥2-step DRSS improvement vs. 3.3% sham (p<0.0001); no vasculitis.
DAYBREAK Phase 3 topline in wet AMD September 2026; PEAK topline in MESI 4Q 2026.
R&D expenses rose to $48.5M from $43.6M driven by PEAK/PINNACLE and DAYBREAK studies.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kodiak Sciences Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the first quarter of 2026 was $58.2 million, EPS $0.94 per share on a basic and diluted basis.

Period: first quarter ended March 31, 2026
Net income: Net loss for the first quarter of 2026 was $58.2 million
EPS: $0.94 per share on a basic and diluted basis
Result: reported results

Exact text from the filing

Net loss for the first quarter of 2026 was $58.2 million, or $0.94 per share on a basic and diluted basis, as compared to a net loss of $57.5 million, or $1.09 per share on a basic and diluted basis, for the first quarter of 2025.

View on SEC.gov

Browse all earnings releases →

Kodiak Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-211811

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.